Establishes provisions relating to the coverage of prescription insulin drugs under certain policies of health insurance. (BDR 57-1167)
AB555 establishes a statewide cap on out-of-pocket cost sharing for prescription insulin drugs under a broad range of private and quasi-private health coverage arrangements in Nevada. For covered insulin prescriptions, insurers, carriers, societies, hospital and medical services corporations, health maintenance organizations, prepaid limited health service organizations, and managed care organizations may not charge more than $35 for a 30-day supply through a deductible, copayment, coinsurance, or other cost-sharing obligation. The bill defines prescription insulin drugs as insulin-containing prescription drugs used to control blood glucose for diabetes, and it applies to type I, type II, and gestational diabetes.
The bill also amends existing diabetes-coverage statutes so that the new insulin cost-sharing cap overrides prior provisions requiring diabetes benefits to be subject to the same deductible and copayment terms as other covered services. It authorizes the Insurance Commissioner to enforce compliance, including by suspending or revoking certificates of authority in certain cases, and extends the requirement to some out-of-state policies issued by domestic insurers when permitted by the other state’s regulatory structure. The bill excludes certain coverage arrangements from the new requirement, including Medicaid managed care, CHIP, and some public employee and local government plans, and it applies prospectively to policies and plans issued on or after October 1, 2025, including renewals and extensions.
AB555 would amend multiple chapters of Nevada insurance law to create a uniform insulin affordability standard across most private health coverage markets. It changes existing diabetes-coverage provisions in NRS chapters 689A, 689B, 695B, and 695C so that insurers can no longer rely on general parity language to charge higher cost sharing for insulin than for other diabetes-related benefits. The bill also adds parallel requirements for fraternal benefit societies, prepaid limited health service organizations, and managed care organizations, while giving the Insurance Commissioner enforcement authority over noncompliant entities.
The bill appears to have been broadly supported. It passed the Assembly unanimously, 42-0, and the Senate by a strong margin, 18-2. That voting pattern suggests general bipartisan agreement with limiting insulin costs and improving affordability for people with diabetes. The emergency-request framing also indicates a sense of urgency around the issue.
The main policy tension in AB555 is between consumer affordability and insurer flexibility in benefit design. The bill specifically overrides existing statutory language that otherwise allows diabetes coverage to be subject to the same deductibles and copayments as other services, which may concern insurers and managed care organizations that prefer uniform cost-sharing rules. Another point of distinction is the bill’s carve-outs: it excludes Medicaid, CHIP, and certain public employee or local government coverage arrangements, meaning the new cap is not universal across all Nevada health coverage. The limited opposition reflected in the Senate vote suggests any concerns were relatively narrow and did not prevent passage.